HYBRID WEBINAR

Intellectual Property and Competition Policy in the Pharmaceutical Industry – Regulatory and Competition Perspectives

organized by

the World Intellectual Property Organization (WIPO)

in cooperation with

the International Generic and Biosimilar Medicines Association (IGBA), and
the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

WIPO Headquarters

October 19, 2022 – 10.30 to 12.00 CEST

PROVISIONAL PROGRAM

prepared by the International Bureau of WIPO
Wednesday, October 19, 2022

10.30 – 10.40  **Introductory remarks**

   **Speaker:** Mr. Giovanni Napolitano, Director, IP and Competition Policy, Global Challenges and Partnerships Sector, WIPO, Geneva

10.40 – 11.00  **The main issues at the intersection of IP and Competition: An Overview**

   **Speaker:** Mr. David Reed, Adjunct Professor for International Business Transactions, Syracuse University College of Law, USA

11.00 – 11.15  **The main issues at the intersection of IP and Competition: The Perspective of Generic and Biosimilar Industry**

   **Speaker:** Mr. Adrian van den Hoven, Director General of Medicines for Europe, International Generic and Biosimilar medicines Association (IGBA) founding Member

11.15 – 11.30  **The main issues at the intersection of IP and Competition: The Perspective of Pharmaceuticals Manufacturers**

   **Speaker:** Ms. Melinda Friend, General Counsel, International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)

11.30 – 11.45  **The main issues at the intersection of IP and Competition: The Regulatory and Competition Perspective**

   **Speaker:** Mr. Luca Arnaudo, Senior officer, Italian Medicines Agency (AIFA), Italy

11.45 – 12.00  **Q&A**

   **Final Remarks**

[End of document]